Clinical trials: Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
The investigators are trying to learn more about the cause of kidney diseases such as Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic syndrome by studying genetics.
- Conditions
- Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, End Stage Renal Disease, Kidney Failure
- Trial name
- FSGS (NCT02194582)
- Where
- United States
- Volunteers
- 2,050 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Focal Segmental Glomerulosclerosis
Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis
The aim of this clinical trial is to determine the effect and security of low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis.
- Trial name
- NCT00956059
- Testing
- prednisone, FK506, MMF, prednisone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xi'an Jiaotong University
Glomerulosclerosis, Focal Segmental, Minimal Change Disease
The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)
In a monocentric, later multicentric prospective approach the FOrMe registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) aims to generate a longitudinal cohort of 150 pediatric cases of…
- Conditions
- Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Idiopathic Nephrotic Syndrome
- Trial name
- FOrMe (NCT03949972)
- Testing
- Biosampling
- Where
- 12 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Prof. Dr. Paul Brinkkoetter
Focal Segmental Glomerulosclerosis
Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5
This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with…
- Trial name
- NCT00816504
- Testing
- Galactose
- Where
- United States
- Sponsor
- Northwell Health
Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome
SLIT ABS: Study on Patients With Autoimmune Podocytopathy
Nephrotic syndrome is a kidney condition that mainly affects children and is characterized by high levels of protein in the urine, low levels of protein in the blood, and swelling.
- Conditions
- Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
- Trial name
- NCT07516964
- Testing
- Serum and renal tissue analysis
- Where
- 14 sites in United States, Germany and 3 more
- Volunteers
- 50 people
- Sponsor
- Meyer Children's Hospital IRCCS
Focal Segmental Glomerulosclerosis
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
This is a pilot/feasibility, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to or at the time of kidney transplantation can prevent recurrent FSGS in children…
- Trial name
- NCT03763643
- Testing
- Rituximab, Plasmapheresis
- Where
- 12 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Minnesota
Focal Segmental Glomerulosclerosis
Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
The purpose of this study is to evaluate the safety and tolerability of FG-3019 administered over 8 weeks to adolescent and adult subjects with steroid-resistant focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT00782561
- Testing
- FG-3019
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Kyntra Bio
Focal Segmental Glomerulosclerosis, Proteinuria
ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank
Nephrotic syndrome is the clinical phenotype of a heterogeneous group of glomerular diseases that may present with varying degrees of urinary protein loss (proteinuria), dysproteinemia in the blood, fluid retention and impaired…
- Conditions
- Focal Segmental Glomerulosclerosis, Proteinuria, Nephrotic Syndrome, Nephrotic Syndrome Steroid-Resistant
- Trial name
- NCT06162546
- Testing
- Registry
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Christoph Aufricht
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis
Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
The purpose of this study is evaluate if abatacept is effective and safe in decreasing the level of protein loss in the urine in patients with excessive loss of protein in the urine (nephrotic syndrome) due to either focal…
- Conditions
- Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT02592798
- Testing
- Abatacept, Normal Saline, D5W
- Where
- 27 sites in United States
- Volunteers
- 36 people
- Sponsor
- Bristol-Myers Squibb
Focal Segmental Glomerulosclerosis, HIV-Associated Focal Segmental Glomerulosclerosis
Genetic Markers for Focal Segmental Glomerulosclerosis
Glomerulonephritis is a disease which affect the kidneys. Occasionally these diseases can progress to a loss of kidney function in some patients.
- Trial name
- NCT00001393
- Where
- United States
- Volunteers
- 616 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Glomerular Disease
Vitamin D Supplementation in Glomerular Disease
This multi-site, pilot study will assess vitamin D supplementation in children and young adults with Glomerular Disease. .
- Trial name
- NCT01835639
- Testing
- Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Children's Hospital of Philadelphia
Nephrotic Syndrome in Children, Nephrotic Syndrome, Minimal Change
REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)
This is a pilot feasibility study for a proposed full-scale randomized controlled trial to evaluate the effectiveness and safety of a reduced-dose oral prednisone (steroids) regimen to treat childhood steroid-sensitive nephrotic…
- Conditions
- Nephrotic Syndrome in Children, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome, Nephrotic Syndrome，Idiopathic
- Trial name
- RESPONSE (NCT06635720)
- Testing
- Prednisone
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- The Hospital for Sick Children
Focal Segmental Glomerulosclerosis
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).
- Trial name
- DUPLEX (NCT03493685)
- Testing
- sparsentan, Irbesartan
- Where
- 226 sites in United States, Argentina and 20 more
- Volunteers
- 371 people
- Sponsor
- Travere Therapeutics, Inc.
Microbiota, B-lymphocytes
INS, B Cells and Microbiota
Idiopathic nephrotic syndrome (NIS) is a clinical entity defined by the association of selective albuminuria, hypoalbuminemia, and nonspecific glomerular lesions (lesions minimal glomerular (LGM) or segmental and focal hyalinosis…
- Conditions
- Microbiota, B-lymphocytes, Glomerulosclerosis, T-lymphocytes
- Trial name
- NCT04924712
- Testing
- Measurement of blood immune populations and microbiota distribution.
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
Focal Segmental Glomerulosclerosis
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
PODOMOUNT-pFSGS This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT07220083
- Testing
- BI 764198
- Where
- 315 sites in United States, Argentina and 38 more
- Volunteers
- 286 people
- Sponsor
- Boehringer Ingelheim
Focal Glomerulosclerosis
Sirolimus for Focal Segmental Glomerulosclerosis
This study will determine the safety and effectiveness of sirolimus (Rapamune® (Registered Trademark)) in treating focal segmental glomerulosclerosis (FSGS), a disease involving kidney scarring and increased protein in the urine.
- Trial name
- NCT00040508
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Focal Segmental Glomerulosclerosis
Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
This project will test whether adalimumab,and/or galactose can safely reduce proteinuria (abnormal amounts of protein in the urine) and protect kidney function better than standard treatment for patients with focal segmental…
- Trial name
- FONTII (NCT00814255)
- Testing
- Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
- Where
- 18 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- NYU Langone Health
Childhood Idiopathic Nephrotic Syndrome
Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood
Background Idiopathic nephrotic syndrome is a rare disease beginning during childhood and treated with immunosuppressants (i.e. steroids, mycophenolate mofetil, cyclophosphamide, cyclosporine).
- Trial name
- NEPHRUTIX (NCT01268033)
- Testing
- Rituximab
- Where
- 24 sites in Belgium, France
- Volunteers
- 26 people
- Sponsor
- University Hospital, Limoges
Nephrosis, Focal Lipoid Glomerulosclerosis
Steroid Treatment for Kidney Disease
Focal segmental glomerulosclerosis (FSGS) and minimal change disease are kidney diseases that are associated with increased excretion of protein in the urine.
- Trial name
- NCT00065611
- Testing
- Oral dexamethasone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nephrotic Syndrome
Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)
Background. Patients, especially children, with steroid-dependent or multirelapsing nephrotic syndrome (NS) secondary to minimal change disease (MCD) or idiopathic focal and segmental glomerulosclerosis (FSGS) on continuous…
- Trial name
- NEMO (NCT00981838)
- Testing
- Rituximab
- Where
- 7 sites in Italy
- Volunteers
- 24 people
- Sponsor
- Mario Negri Institute for Pharmacological Research